Skip to main content
Caplight Logo









Bridge to Life

Bridge to Life

Private
Duluth, GeorgiaHealthcare & Life Scienceshttps://bridgetolife.com/

Last Round

Series C

Aug 12, 2026

Est. Valuation

$470M

Total Funding Raised

$237M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Bridge to Life is a biotechnology company that develops and markets innovative organ preservation and machine perfusion technologies to improve transplant outcomes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Non-AI

Keywords

organ preservationhypothermic oxygenated perfusionHOPEmachine perfusiontransplant technologyorgan viabilityorgan transplanttransplant logisticsmedical deviceorgan procurementischemia-reperfusion injurytransplant perfusionmarginal donor organsorgan preservation solution

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bridge to Life Comparables

Compare Bridge to Life with similar companies based on industry and business-model similarity.

Bridge to Life comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Getinge AB
86%
Shanghai Genext Medical Technology Co., Ltd.
82%
Xvivo Perfusion
81%

Bridge to Life Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 12, 2026
Series A ExtensionAug 28, 2024
StrategicAug 2, 2023
DebtAug 19, 2021
VC RoundJan 21, 2009

Key People

Founding team and executive leadership

Don Webber

President and CEO

Executive Team

Stevan Schweighardt

Chairman CEO

Executive Team

Brian Lenz

Chief Financial Officer

Executive Team

Bridge to Life Investors

Notable investors and investment history

Bridge to Life investors
InvestorRounds
Soleus CapitalSeries C
Perceptive AdvisorsDebt
Lauxera Capital PartnersSeries C
Wisconsin Alumni Research FoundationVC Round
SCRAVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 12, 2026

    $110M round led by Soleus Capital

  • Mar 24, 2026

    VitaSmart HOPE System received FDA clearance for US commercial use.

Bridge to Life Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bridge to Life Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bridge to Life's valuation, stock price, and market status.

Firmographic Details

HeadquartersDuluth, Georgia
Employee Range89
Year Founded2005
Last FundingAug 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?